» Articles » PMID: 34445786

Diabetic Kinome Inhibitors-A New Opportunity for β-Cells Restoration

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Aug 27
PMID 34445786
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Diabetes, and several diseases related to diabetes, including cancer, cardiovascular diseases and neurological disorders, represent one of the major ongoing threats to human life, becoming a true pandemic of the 21st century. Current treatment strategies for diabetes mainly involve promoting β-cell differentiation, and one of the most widely studied targets for β-cell regeneration is DYRK1A kinase, a member of the DYRK family. DYRK1A has been characterized as a key regulator of cell growth, differentiation, and signal transduction in various organisms, while further roles and substrates are the subjects of extensive investigation. The targets of interest in this review are implicated in the regulation of β-cells through DYRK1A inhibition-through driving their transition from highly inefficient and death-prone populations into efficient and sufficient precursors of islet regeneration. Increasing evidence for the role of DYRK1A in diabetes progression and β-cell proliferation expands the potential for pharmaceutical applications of DYRK1A inhibitors. The variety of new compounds and binding modes, determined by crystal structure and in vitro studies, may lead to new strategies for diabetes treatment. This review provides recent insights into the initial self-activation of DYRK1A by tyrosine autophosphorylation. Moreover, the importance of developing novel DYRK1A inhibitors and their implications for the treatment of diabetes are thoroughly discussed. The evolving understanding of DYRK kinase structure and function and emerging high-throughput screening technologies have been described. As a final point of this work, we intend to promote the term "diabetic kinome" as part of scientific terminology to emphasize the role of the synergistic action of multiple kinases in governing the molecular processes that underlie this particular group of diseases.

Citing Articles

Design, synthesis, and structure-activity relationship studies of 6-benzo[]indeno[1,2-]thiophen-6-one derivatives as DYRK1A/CLK1/CLK4/haspin inhibitors.

Faouzi A, Arnaud A, Halle F, Roussel J, Aymard M, Denavit V RSC Med Chem. 2024; .

PMID: 39430953 PMC: 11487425. DOI: 10.1039/d4md00537f.


Targeting Protein Kinases to Protect Beta-Cell Function and Survival in Diabetes.

Dalle S Int J Mol Sci. 2024; 25(12).

PMID: 38928130 PMC: 11203834. DOI: 10.3390/ijms25126425.


Hyperglycemia activates FGFR1 TLR4/c-Src pathway to induce inflammatory cardiomyopathy in diabetes.

Chen X, Qian J, Liang S, Qian J, Luo W, Shi Y Acta Pharm Sin B. 2024; 14(4):1693-1710.

PMID: 38572108 PMC: 10985127. DOI: 10.1016/j.apsb.2024.01.013.


Binding mechanism and biological effects of flavone DYRK1A inhibitors for the design of new antidiabetics.

Pustelny K, Grygier P, Barzowska A, Pucelik B, Matsuda A, Mrowiec K Sci Rep. 2023; 13(1):18114.

PMID: 37872245 PMC: 10593742. DOI: 10.1038/s41598-023-44810-3.


DYRK1A inhibitors leucettines and TGF-β inhibitor additively stimulate insulin production in beta cells, organoids, and isolated mouse islets.

Pucelik B, Barzowska A, Czarna A PLoS One. 2023; 18(5):e0285208.

PMID: 37195917 PMC: 10191338. DOI: 10.1371/journal.pone.0285208.


References
1.
Muller T, Clemmensen C, Finan B, DiMarchi R, Tschop M . Anti-Obesity Therapy: from Rainbow Pills to Polyagonists. Pharmacol Rev. 2018; 70(4):712-746. DOI: 10.1124/pr.117.014803. View

2.
Skurat A, Dietrich A . Phosphorylation of Ser640 in muscle glycogen synthase by DYRK family protein kinases. J Biol Chem. 2003; 279(4):2490-8. DOI: 10.1074/jbc.M301769200. View

3.
Park J, Song W, Chung K . Function and regulation of Dyrk1A: towards understanding Down syndrome. Cell Mol Life Sci. 2009; 66(20):3235-40. PMC: 11115655. DOI: 10.1007/s00018-009-0123-2. View

4.
. 9. Pharmacologic Approaches to Glycemic Treatment: . Diabetes Care. 2018; 42(Suppl 1):S90-S102. DOI: 10.2337/dc19-S009. View

5.
Rad S, Arya A, Karimian H, Madhavan P, Rizwan F, Koshy S . Mechanism involved in insulin resistance via accumulation of β-amyloid and neurofibrillary tangles: link between type 2 diabetes and Alzheimer's disease. Drug Des Devel Ther. 2018; 12:3999-4021. PMC: 6255119. DOI: 10.2147/DDDT.S173970. View